Propella Therapeutics Announces Presentation of Updated Phase 1/2a Data of PRL-02 for the Treatment of Advanced Prostate Cancer at 2023 ASCO Genitourinary (GU) Cancers Symposium
PRL-02 continues to demonstrate strong safety along with dose-dependent reductions in testosterone and PSA Recently issued U.S. patent expands PRL-02...